🏛️ Verified NIH Record • Updated 2026-04-30
Ocular Proteomics Testing In Chronic Atrophy (NCT07298291)
A Phase 1, Single-Center, Prospective Study to Evaluate the Safety and Clinical Utility of Anterior Chamber Paracentesis for Proteomic Analysis in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
🔵 Active, Not Recruiting Observational / Diagnostic 🩺 Clinical Procedure Protocol Sponsor: ClinOmicsAI
🩺 Plain-English Summary (8th-Grade Level)
Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
Who can join: Review the eligibility criteria below.
Location: Erie Retina Research — Erie, Pennsylvania
Age range: 50 Years to 89 Years
🧪 Interventions in This Study
- AC Tap (anterior chamber paracenthesis) (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Erie Retina Research — Erie, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related (Dry) Macular Degeneration
- Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection — Woodbridge, New Jersey
Explore by condition: All Age-Related (Dry) Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.